Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
13.36
+0.19 (1.44%)
At close: Dec 20, 2024, 4:00 PM
13.45
+0.09 (0.67%)
After-hours: Dec 20, 2024, 4:07 PM EST
Myriad Genetics Revenue
Myriad Genetics had revenue of $213.30M in the quarter ending September 30, 2024, with 11.15% growth. This brings the company's revenue in the last twelve months to $823.60M, up 12.15% year-over-year. In the year 2023, Myriad Genetics had annual revenue of $753.20M with 11.03% growth.
Revenue (ttm)
$823.60M
Revenue Growth
+12.15%
P/S Ratio
1.45
Revenue / Employee
$305,037
Employees
2,700
Market Cap
1.22B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
Dec 31, 2021 | 690.60M | 133.60M | 23.99% |
Dec 31, 2020 | 557.00M | -81.60M | -12.78% |
Jun 30, 2020 | 638.60M | -212.50M | -24.97% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 2.01B |
Progyny | 1.14B |
Embecta | 1.12B |
Artivion | 384.90M |
STAAR Surgical Company | 341.22M |
Ardelyx | 251.85M |
Weave Communications | 195.84M |
Harrow | 169.14M |
MYGN News
- 2 days ago - Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics - GlobeNewsWire
- 11 days ago - Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing - GlobeNewsWire
- 11 days ago - Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member - GlobeNewsWire
- 12 days ago - Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium - GlobeNewsWire
- 4 weeks ago - Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 - GlobeNewsWire
- 4 weeks ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 4 weeks ago - Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 5 weeks ago - Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation - Accesswire